Abstract
Cancer has become a major worldwide problem and drug resistance now is one of the most important problems in treatment of cancer. Anthraquinone derivatives represent one of the most important drugs that can be used in treatment of many types of cancer. In this study two series of novel bis-anthraquinone derivatives have been synthesized. Five of these compounds were chosen to be evaluated for their antitumor activity against human cancer cell lines by the National Cancer Institute (NCI, USA). Marked activity was shown for the tested compounds(2–6). The most active one was compound 6 with mean value −67.00 against all cell lines. Compounds 7 and 8 were found inactive.
Graphical Abstract
.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baguley, B.C., W.A. Denny, G.J. Atwell, and B.F. Cain. 1981. Journal of Medicinal Chemistry 24: 520–525.
Boyd, M.R., and K.D. Paull. 1995. Drug Development Research 34: 91–109.
Brana, M.F., J.M. Castellano, M. Moran, M.J. Perezdevega, D. Perron, D. Conlon, P.F. Bousquet, C.A. Romerdahl, and S.P. Robinson. 1996. Anti-Cancer Drug Design 11: 297–309.
Cholody, W.M., L. Hernandez, L. Hassner, D.A. Scuderio, D.B. Djurickovic, and C.J. Michejda. 1995. Journal of Medicinal Chemistry 38: 3043–3052.
Denny, W.A. 1989. Anti-Cancer Drug Design 4: 241–263.
Gamage, S.A., J.A. Spicer, G.J. Atwell, G.L. Finaly, B.C. Baguley, and W.A. Denny. 1999. Journal of Medicinal Chemistry 42: 2383–2393.
Gholivand, M.B., S. Kashanian, H. Peyman, and H. Roshanfekr. 2011. European Journal of Medicinal Chemistry 46: 2630–2638.
Gray, G.D., and E. Wickstrom. 1996. BioTechniques 21: 780–782.
Grever, M.R., S.A. Schepartz, and B.A. Chabner. 1992. The National Cancer Institute: cancer drug discovery and development program. Seminars in Oncology 19: 622–638.
Hajihassan, Z., and A. Rabbani-chadegani. 2011. International Journal of Biological Macromolecules 48: 87–92.
Hsin, L.W., Wang, H.|P., Kao, P.H., Lee, O., Chen, W.R., Chen, H.W., Guh, J.H., Chan, Y.L., His, C.P., Yang, M.S., Li, T.K., and C.H. Lee. 2008. Bioorganic and Medicinal Chemistry 16: 1006–1014.
Janouec, L., M. Kozurkova, D. Sabolova, J. Varsky, H. Paulikova, J. Plsikova, Z. Vantova, and J. Imrich. 2011. Bioorganic and Medicinal Chemistry 19: 1790–1801.
Lin, L., W.Q. Lin, J.H. Jiang, G.L. Shen, and R.Q. Yu. 2005. European Journal of Pharmaceutical Sciences 25: 245–254.
Monks, A., D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, D. Vistica, C. Hose, J. Langley, P. Cronise, and A. Vaigro-Wolff. 1991. Journal of the National Cancer Institute 83: 757–766.
Sato, S., M. Iwaizumi, K. Handa, and Y. Tamwea. 1977. Gann 68: 603–608.
Skehan, P., R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.R. Warren, H. Bokesch, S. Kenney, and M.R. Boyd. 1990. Journal of the National Cancer Institute 82: 1107–1112.
Qin, Y., J.Y. Porg, W.H. Chen, Z. Cai, and Z.H. Jiang. 2006. Bioorganic and Medicinal Chemistry 14: 25–32.
Wakelin, L.P.G. 1986. Medicinal Research Reviews 6: 275–340.
Acknowledgments
The authors wish to thank the National Cancer Institute, U.S.A. for carrying the antitumor screening for the new compounds.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Taher, A.T., Hegazy, G.H. Synthesis of novel bis-anthraquinone derivatives and their biological evaluation as antitumor agents. Arch. Pharm. Res. 36, 573–578 (2013). https://doi.org/10.1007/s12272-013-0074-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-013-0074-x